Related references
Note: Only part of the references are listed.Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer
Elie Hatem et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Johann S. de Bono et al.
LANCET ONCOLOGY (2019)
The Tissue Factor Pathway and Wound Healing
Maureane Hoffman
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2018)
Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio anubis) model of endometriosis
Demetra Hufnagel et al.
REPRODUCTIVE BIOLOGY (2018)
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON
Zhiwei Hu et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Rohtesh S. Mehta et al.
FRONTIERS IN IMMUNOLOGY (2018)
Treating Tissue Factor-Positive Cancers with Antibody-Drug Conjugates That Do Not Affect Blood Clotting
Jan-Willem Theunissen et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Therapeutic Antibody-Like Immunoconjugates against Tissue Factor with the Potential to Treat Angiogenesis-Dependent as Well as Macrophage-Associated Human Diseases
Zhiwei Hu
ANTIBODIES (2018)
Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy
Zhiwei Hu et al.
ANGIOGENESIS (2017)
Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer
Zhiwei Hu et al.
ONCOTARGET (2017)
Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice
Qing Zhang et al.
ONCOTARGET (2017)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay
E. Verronese et al.
ONCOIMMUNOLOGY (2016)
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paulina J. Paszkiewicz et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8
Qi Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin
Gabriela Cesarman-Maus et al.
THROMBOSIS RESEARCH (2014)
Molecularly targeted therapies for metastatic triple-negative breast cancer
Soley Bayraktar et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman et al.
PLOS ONE (2012)
Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer
Cornelia Liedtke et al.
BREAST CARE (2011)
Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy
J. Duanmu et al.
BRITISH JOURNAL OF CANCER (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Metastatic Triple-negative Breast Cancer
E. A. Rakha et al.
CLINICAL ONCOLOGY (2011)
Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy
J. Cheng et al.
CURRENT CANCER DRUG TARGETS (2011)
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
Emilie Mamessier et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Triple-Negative Breast Cancer: An Unmet Medical Need
Clifford A. Hudis et al.
ONCOLOGIST (2011)
Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer
Abderrahim El Guerrab et al.
PLOS ONE (2011)
Regulation of NK92-MI Cell Cytotoxicity by Substance P
W. X. Fu et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
The Immunoconjugate Icon Targets Aberrantly Expressed Endothelial Tissue Factor Causing Regression of Endometriosis
Graciela Krikun et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
N. Berrada et al.
ANNALS OF ONCOLOGY (2010)
Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice
Zhiwei Hu et al.
BMC CANCER (2010)
Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer
Zhiwei Hu et al.
BMC IMMUNOLOGY (2010)
Tissue factor in cancer progression and angiogenesis
Wolfram Ruf et al.
THROMBOSIS RESEARCH (2010)
Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
Farrah Kassam et al.
CLINICAL BREAST CANCER (2009)
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
Carey K. Anders et al.
CLINICAL BREAST CANCER (2009)
Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL)
Alan S. Wayne et al.
BLOOD (2009)
Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia
Anna G. McDonald et al.
BLOOD (2008)
Targeting tissue factor for immunotherapy of choroidal neovascularization by intravitreal delivery of factor VII-Fc chimeric antibody
Tongalp H. Tezel et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2007)
Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies
C. Lopéz-Pedrera et al.
LEUKEMIA (2006)
Tissue factor in cancer and angiogenesis: The molecular link between genetic tumor progression, tumor neovascularization, and cancer Coagulopathy
J Rak et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Tissue factor signal transduction in angiogenesis
HH Versteeg et al.
CARCINOGENESIS (2003)
Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration
PS Bora et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer
ZW Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy
ZW Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
